Loading clinical trials...
Loading clinical trials...
SCLC has a very high degree of malignancy, and 60% to 70% of patients are diagnosed as extensive stage. The median survival of patients with limited-stage disease is about 15-20 months, and the median...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Henan Cancer Hospital
NCT07413042 · SCLC, Extensive Stage
NCT07321574 · SCLC, Extensive Stage, Advanced Solid Tumors
NCT07136285 · SCLC, Extensive Stage
NCT07400575 · NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage
NCT07308379 · SCLC, Extensive Stage, Toripalimab
Henan Tumor Hospital
Zhengzhou, Henan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions